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Atopic dermatitis (AD) is a common chronic skin inflammatory disease. Long-term use of topical corticosteroids
in skin inflammation poses risks of systemic and local side effects. The NF-kB transcription factor family plays a
central role in the progression and maintenance of AD. This study explores the possibility of using topical NF-kB
Decoy as a novel therapeutic alternative for targeting Th1/Th2-driven skin inflammation in experimental AD.
A high-affinity, topical NF-kB Decoy developed for human efficacy demonstrates: (i) efficient NF-kB Decoy
penetration in pig skin, (ii) NF-kB Decoy nuclear localization in keratinocytes and key immune cells, and (iii)
potent ‘‘steroid-like’’ efficacy in a chronic dust-mite antigen skin inflammation treatment model. NF-kB Decoy
exerts its anti-inflammatory action through the effective inhibition of essential regulators of inflammation and
by induction of apoptosis of key immune cells. Unlike betamethasone valerate (BMV), long-term NF-kB Decoy
treatment does not induce skin atrophy. Moreover, topical NF-kB Decoy, in contrast to BMV, restores
compromised stratum corneum integrity and barrier function. Steroid withdrawal causes rapid rebound
of inflammation, while the NF-kB Decoy therapeutic benefit was maintained for weeks. Thus, topical NF-kB
Decoy provides a novel mechanism of reducing chronic skin inflammation with improved skin homeostasis
and minimal side effects.
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INTRODUCTION
Atopic dermatitis (AD) is a chronic inflammatory pruritic skin
disease with a relapsing course that has gross impact on
the patient’s life style. Significant challenges that patients
confront include severe discomfort, secondary infections,
impaired social interactions, and sleep disturbances
(Finlay, 1996; Leung, 1997a; Fortune et al., 2005). Although
corticosteroids are common and effective in the treatment of
skin inflammation, chronic use is discouraged due to
potential side effects such as skin atrophy and pronounced
symptomatic rebound following discontinuation of therapy,
especially with mid- or high-strength topical steroids such
as topical betamethasone valerate (BMV) (Barnes, 1998;
Schacke et al., 2002). Recently, the development of steroid-
free treatment alternatives has provided some benefit to
patients with AD. Specifically, in AD two topical calcineurin
inhibitors have been approved (pimecrolimus and tacrolimus)
that show efficacy in mild to moderate and severe disease,
respectively (Nghiem et al., 2002). However, the side
effects associated with increased systemic absorption of these
molecules have led investigative dermatologists to continue
with the development of primarily localized therapeutic
alternatives for AD (Schacke et al., 2002; Becker et al., 2006).
The cutaneous lesions associated with AD result from the
local expression of proinflammatory cytokines and chemo-
kines. Cytokines such as tumor necrosis factor-alpha (TNF-a),
IL-1a, and IL-1b from resident cells and activation of Toll-like
receptors in response to microbial infection activate the
NF-kB pathway which in turn leads to the coordinated
transactivation of key cytokines and adhesion molecules
involved with the pathogenesis of inflammatory diseases
(Kupper, 1990; Barnes, 1996; Barnes and Karin, 1997;
Medzhitov et al., 1997). Futhermore, in AD lesions, IgE
receptors (Fc (epsilon) RI) are upregulated on Langerhans
cells and upon ligation secrete TNF-a and monocyte
chemotactic protein-1 (MCP-1), which can be blocked by
NF-kB inhibitors (Kraft et al., 2002; Novak et al., 2004). As
NF-kB plays such a significant role in the pathogenesis of AD,
there has been an increased effort to develop topical
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therapies specifically targeting the NF-kB pathway (Leung,
2000; Nakamura et al., 2002a; Zheng et al., 2003; Furukawa
et al., 2004).
Avenues of investigative research for blocking NF-kB
activity include small molecules, neutralizing antibodies,
RNAi, and transcription factor (TF) Decoys. TF Decoys are
double-stranded DNA oligonucleotides (ODN), analogs of
genomic TF-binding sequences which, when transfected into
cells, competitively bind to the native TF and prevent
activation of target genes (Dzau et al., 1996; Morishita
et al., 1997; Nakamura et al., 2002b). Since the molecular
weight of these drugs is relatively high, initial treatment
efforts have focused on compromised AD skin (Nakamura
et al., 2002a). The well-established contribution of NF-kB to
the pathogenesis of AD highlights the need for advanced
therapeutic control of this signaling pathway in next
generation treatments. Several studies have demonstrated
the anti-inflammatory effects of NF-kB Decoy ODN in
in vitro and in vivo mouse models (Dzau et al., 1996;
Morishita et al., 1997; Nakamura et al., 2002b). However,
specific questions regarding the skin penetration, immune
cell uptake, mechanism of action, and possible local side
effects associated with treatment of topical NF-kB Decoy
remain unclear.
We have designed a target-specific fully phosphoro-
thioated ODN NF-kB Decoy and a formulation for the
effective topical delivery of ODNs. This study is the first
demonstration of an effective ‘‘non-viral’’ topical delivery
of Decoy into pig skin. We demonstrate that topical
NF-kB Decoy ODN can ameliorate skin inflammation in an
established chronic AD mouse model. In inflamed skin,
topical NF-kB Decoy treatment, similarly to BMV, induces
apoptosis, decreases epidermal and dermal cell proliferation
and downregulates both Th1- and Th2-related pro-inflamma-
tory genes such as IL-1b, IFNg, IL-4, IL-13, and TNF-a.
Topical NF-kB Decoy treatment does not induce skin atrophy
and restores inflammation-compromised skin barrier func-
tion. Consistent with this, NF-kB Decoy withdrawal does not
lead to a rapid flare-up of skin inflammation as seen with
BMV. Topical NF-kB Decoy thus provides a safe and novel
anti-inflammatory treatment that restores cutaneous homeo-
stasis by normalizing immune cell and barrier function.
RESULTS
NF-jB Decoy reduces ear swelling in chronic inflammation
The effects of topical NF-kB Decoy treatment were examined
in an established chronic AD model. Ear thickness measure-
ments were performed on Dermatophagoides pteronyssinus
(Dp) extract-injected NC/Nga (Nishiki-Nezumi) mice
on alternate days, for 11 days. Initiation of topical NF-kB
Decoy or BMV treatment followed on day 12 (b.i.d.). A dose-
dependent inhibition of inflammation following NF-kB
Decoy treatment was observed (Figure 1a). The highest
topical dose of 1% NF-kB Decoy inhibited inflammation by
74%, similar to topical BMV. Ears treated with scramble
ODN, vehicle only, or ears left untreated maintained severe
ear thickness (Figure 1a and data not shown). These data
demonstrate that topical NF-kB Decoy is effective in reducing
chronic skin inflammation in a mouse treatment model.
The efficacy of topical NF-kB Decoy was also assessed in
an acute 12-O-tetradecanoylphorbol 13-acetate-induced skin
inflammation model. 12-O-tetradecanoylphorbol 13-acetate-
induced ear swelling was reduced following application of
topical NF-kB Decoy; the highest dose (1%) showed similar
efficacy to BMV treatment, with over 70% inhibition of ear
swelling (data not shown).
Gel shift assays were performed with labeled probe and
nuclear extracts of inflamed Dp-injected ears to determine
NF-kB Decoy-dependent competitive inhibition to NF-kB
protein. Nuclear extracts from inflamed ears of NC/Nga mice
showed three strong DNA–protein complexes with low
mobility (Figure 1b, indicated by a bracket). A reduction in
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Figure 1. NF-jB Decoy efficacy in mouse inflammation model. (a) NC/Nga
mice-injected intradermally with Dp extract showed ear swelling. Treatments
initiated on day 11 (indicated by the arrow) include 1% scramble ODN, 0.25
and 1% NF-kB Decoy, and 0.1% BMV. Data are plotted as mean7SEM
(n¼8, *Po0.001). These results are representative of 10 independent
experiments. (b) NF-kB levels were detected by electrophoretic mobility shift
assay analysis using 32P-labeled probe and nuclear extracts prepared from
control, inflamed, 1% scramble ODN, 1% Decoy, or BMV-treated NC/Nga
ears. The identity of the NF-kB proteins contained in complexes bound to the
radiolabeled oligonucleotide probe were identified by pre-incubating extracts
with antibodies specific for each NF-kB family member. The complexes
indicated in the brackets contain p65 and p50 homo and hetrodimers.
Antibody/NF-kB protein complexes of slower mobility are indicated by the
asterisk (right panel; *). These results are representative of three independent
experiments. (c) Quantitation of NF-kB levels was performed by normalizing
the specific band intensities in the gel shift assay to the values obtained from a
TransAM assay performed with the same nuclear extracts for the ubiquitously
expressed TF, NF-YA. The y-axis represents ratios of values for NF-kB band
intensities to NF-YA absorbance readings. Each data point is representative of
four independent ear samples. Compared to the inflamed sample, NF-kB
Decoy (Po0.0038), and BMV (Po0.001) treatment significantly reduced p65/
p50 DNA binding. These results are representative of three independent
experiments.
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the density of the three bands was observed in samples
treated with topical BMV or 1% NF-kB Decoy, while band
densities remained unchanged in samples treated with
scramble ODN. The identity of the p50 and p65 NF-kB
subunits was confirmed by a reduction in mobility following
incubation of the sample extracts with specific antibodies
(Figure 1b; right panel denoted by *). Quantitation of
DNA–protein complexes were assessed by normalizing the
band intensity from the gel shift analysis to the values
obtained from a TransAM assay for the ubiquitously
expressed TF, nuclear factor-YA (NF-YA) (Figure 1c). The
DNA-binding specificity of the NF-kB Decoy was tested
through competitive inhibition of p65, SP1, and NF-YA DNA
binding activity (Figure S1). NF-kB Decoy demonstrates a
dose-dependent inhibition of p65-DNA-binding activity.
Importantly, NF-kB Decoy failed to block the binding activity
of other known ubiquitously expressed TFs including SP1 or
NF-YA (Figure S1).
Topical NF-jB Decoy suppresses inflammation
Histological analyses showed that topical NF-kB Decoy
decreased edema and inflammatory cell infiltrate in skin
lesions induced by Dp injection into ears of NC/Nga mice.
Hematoxylin and eosin-stained sections of untreated lesions
at day 25 reveal a hyperplastic epidermis and edematous
dermis, with an increase in lymphocyte infiltration, clinically
resembling human AD (Figure 2a). In contrast, topical NF-kB
Decoy or BMV treatment produced a similar and significant
decrease in epidermal hyperplasia and cellular infiltration
(Figure 2a). Toludine blue-stained ear sections of both
untreated and scramble ODN-treated lesions showed an
increased number of mast cells (Figure 2b), while inflamed
skin treated with topical NF-kB Decoy or BMV showed fewer
mast cells (Figure 2b). In addition, congo red staining
revealed a decrease in eosinophil infiltration in skin treated
with topical NF-kB Decoy or BMV (Figure 2c). CD4þ T cells
were also decreased with topical NF-kB Decoy and BMV
treatments (Figure 2d). Mice treated with either vehicle
control or scramble ODN fail to reduce such inflammatory
responses. Quantitation of the decrease in mast cells (60%),
eosinophils (70%), and CD4þ T cells (60%) revealed signifi-
cant decreases upon topical NF-kB Decoy or BMV treatment
(Figure 2e).
To examine the specific cellular uptake; topical biotiny-
lated-NF-kB Decoy was applied to Dp-Ag-induced inflamed
ears for 2 days (b.i.d.). NF-kB Decoy (green) distribution in
the epidermal cells and throughout the papillary dermis was
observed (Figure 2f). Immunohistological analysis revealed
an uptake of NF-kB Decoy by several key inflammatory
cells. The colocalization of NF-kB Decoy (green) was
detected in langerin-positive, resident antigen-presenting
cells–Langerhans cells, CD117-positive mast cells, CD4þ
T cells and MCP-1-positive macrophages (all cell markers
in red, Figure 2f).
Topical NF-jB Decoy uptake in porcine skin
Drug delivery in human skin continues to challenge the
development of topical applications for skin diseases.
Although research in rodent models provide valuable
information in skin biology, many preclinical studies in
investigative dermatology are performed preferably in pigs,
since porcine skin is considered to be the best model for
human skin (Bilski and Thomson, 1984; Meingassner and
Stutz, 1992). We demonstrate excellent delivery of topical
NF-kB Decoy into the porcine epidermis and dermis (Figure
3a). Of note, semiquantitative analyses using Image-Pro
software indicate that over 80% of the cells in treated pig
skin are NF-kB Decoy positive (data not shown). We further
confirmed this observation using a quantitative Polymerase
Chain Reaction Pharmacokinetics method to detect the
Decoy (Figure 3b). Uptake and retention of topical NF-kB
Decoy by pig skin following application of a 1% Decoy
topical formulation was 10 ng/mg of tissue processed at
24 hours post-application. Prior tape-stripping of the skin,
to model the compromised barrier in AD, increased the
uptake of an equivalent application to 20 ng Decoy/mg of
tissue (Figure 3b). Overall, these observations confirm
effective NF-kB Decoy delivery into both compromised and
uncompromised skin tissue.
NF-jB Decoy effects on inflammation, apoptosis, and
proliferation
Immunohistological analysis of skin lesions showed an
increase in inflammatory cytokine expression for IL-1b,
TNF-a, macrophage inflammatory protein 2-a precursor and
a key adhesion molecule, ICAM-1 in the inflamed ears
(Figure 4a). Both topical NF-kB Decoy and BMV treatment
decreased the expression of IL-1b, TNF-a, macrophage
inflammatory protein 2-a precursor, and ICAM-1. Tissues
treated with the scramble ODN showed no alteration in the
expression of these molecules. These observations indicate
that inflamed skin cells readily take up NF-kB Decoy and
topical NF-kB Decoy, similar to BMV, suppresses expression
of key regulatory proteins.
For a quantitative measure of the anti-inflammatory effects
of topical NF-kB Decoy and BMV treatment in the Dp-Ag-
inflamed ears, real-time reverse transcriptase-PCR analysis
was performed. NF-kB Decoy and BMV treatment inhibits
mRNA levels of both Th1- and Th2-related proinflammatory
genes including chemokine (C–C motif) receptor 3 (CCR3),
IL-4, ICAM-1, thymic stromal lymphopoietin (TSLP), IL-13,
IFNg, IL-1b, and TNF-a (Figure 4b). These results confirm the
above immunohistochemistry data that NF-kB Decoy down-
regulated important inflammatory-related genes and has a
similar efficacy profile compared to BMV.
Since blockade of NF-kB function is associated with
induction of apoptosis as well as inhibition of proliferation,
we analyzed treated Dp-Ag-inflamed ears by Tunnel assay
and by Ki67 staining (Figure 4c). Enhanced apoptosis (green
nuclei) mediated by BMV and topical NF-kB Decoy
application on inflamed ears was observed, in both the
epidermis and dermis (Figure 4c). In contrast, the scramble
ODN failed to elicit a similar response. Positive Ki67 staining
showed increased proliferation in the epidermal and dermal
layers of inflamed ears (brown nuclei, Figure 4c; lower
panel). Comparative quantitative analyses of both topical
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Figure 2. NF-jB Decoy suppresses inflammation. (a) H&E-stained sections showed Dp-induced hyperproliferation in the epidermis and edematous dermis, with
a massive increase in lymphocyte infiltrations. Sections were observed at an original magnification of 10, bar¼100 mm. (b) Toludine blue-stained skin
sections identify mast cells (arrows). (c) Sections were stained with congo red to quantitate eosiophils (arrows). (d) CD4þ T cells were localized through
immunoflouresence microscopy (arrows). Observations made at an original magnification of  40, bars¼ (b–d) 25 mm. (e) Quantitation of mast cells (*Po0.02
for 0.25% Decoy and Po0.04 for BMV), eosinophils (*Po0.01 for 0.25% Decoy and BMV) and CD4þ T cells was performed from six independent samples.
Data are plotted as mean7SEM. (f) NF-kB Decoy localization in inflamed tissue was performed using 1% biotinylated-NF-kB Decoy. Decoy-treated ears were
counter-stained for CD207þ Langerhans cells, CD4þ T cells, CD117þ mast cells and MCP-1þ macrophages. Laser scanning confocal microscopy images show
Decoy (green) is colocalized with each of these cell markers (red). Sections were observed at an original magnification of 60, bar¼200 mm. Lower panel is a
higher magnification inset.
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NF-kB Decoy and BMV-treated inflamed tissue revealed that
each treatment resulted in a similar outcome: 50–70%
apoptotic cells and a 50% decrease in the mitotic index
(Figure 4d). The number of Ki67-positive cells with scrambled
ODN treatment remained unaffected (Figure 4d). Together,
these observations indicate that NF-kB Decoy exerts its
anti-inflammatory action through the effective inhibition
of essential regulators of inflammation and by induction of
apoptosis of key immune cells.
Lack of skin atrophy with NF-jB Decoy treatment
We tested the local skin-thinning effects of topical applica-
tion of NF-kB Decoy. We performed ear thickness measure-
ments of normal ears treated with BMV or 1% NF-kB Decoy
for 14 days application (b.i.d.). Notably, a dramatic decrease
in ear thickness was observed in response to BMV treatment
(Figure 5a). NF-kB Decoy failed to show any such side effects
of skin atrophy (Figure 5a). Collagen I and III staining was
performed on drug-treated ear sections, which further
confirmed skin-thinning effects of BMV (Figure 5b). Of note,
topical NF-kB Decoy does not cause skin atrophy in a 4-week
dermal pig and a 21-week mouse carcinogenicity study
(Table S1 and data not shown). Furthermore, gene expression
of key extracellular matrix components, including collagen
I and III, tenascin C, and elastin are decreased over 50% by
BMV, without much effect by NF-kB Decoy (Figure 5c).
Overall, long-term treatment of topical NF-kB Decoy does
not decrease the expression of connective tissue genes
associated with skin atrophy.
Withdrawal of topical NF-jB Decoy treatment does not cause
disease rebound and restores epidermal permeability
Potent topical steroid treatment, upon withdrawal is known
to cause severe disease relapse. We next compared the ability
of NF-kB Decoy and steroid treatment to cause rebound of
disease after discontinuation of drug application. Unlike
NF-kB Decoy, cessation of BMV resulted in an immediate
and severe rebound of swelling and inflammation (Figure 6a,
denoted by *). Increase in ear thickness due to BMV with-
drawal was not due to edema, but a hyperplastic epidermis
and dermis, with increased lymphocyte infiltration as
illustrated by hematoxylin and eosin staining (Figure 6b, **
Day 40). A PCR pharmacokinetics study was performed to
determine the presence of NF-kB Decoy after treatment
withdrawal. Rapid clearance of NF-kB Decoy to minimal
levels within 3 days of withdrawal was observed (Figure 6c).
This observation suggests that the maintained anti-inflamma-
tory effect of NF-kB Decoy is not due to an accumulation of
the drug. Furthermore, the absence of therapeutic effective
doses of Decoy in the skin was confirmed by cutaneous
Dp-Ag rechallenge experiments, in which the Decoy-treated
groups showed a similar response to injected dust-mite
antigen as the non-treated or scramble ODN groups (Figure
6d and data not shown). Collectively, these observations
suggest that there is no significant accumulation of Decoy in
the treated tissue and no impaired immune response after 15
days of b.i.d. application.
Rebound caused upon BMV treatment withdrawal, is
known to be associated with barrier disruption; we therefore
measured the effects of BMV and topical NF-kB Decoy on
integrity of mouse stratum corneum (SC) by measuring the
rate of transepidermal water loss (TEWL). Increase of TEWL in
inflamed ears was restored to normal levels by topical
NF-kB Decoy application for 14 days (b.i.d.) (Figure 6e). In
contrast, BMV treatment failed to achieve complete reduction
of TEWL, indicative of the lack of normal restoration of
epidermal permeability. We next assessed if topical NF-kB
Decoy or BMV application (b.i.d., for 14 days) on normal
ears exerts adverse effects on SC function. Neither BMV nor
NF-kB Decoy produced any changes in basal TEWL.
However, unlike NF-kB Decoy that shows normal kinetics
of barrier recovery after acute barrier disruption with acetone,
BMV treatment showed a significant delay of barrier recovery
at 3, 6, and 24 hours (Figure 6f).
Increase in TEWL is associated with dysregulation of
several key regulators of SC integrity. NF-kB Decoy treatment
does not increase expression of inflammation-associated
genes like skin-derived antileukoproteinase (SKALP), cyto-
keratin 6, and CK16 levels, as observed in inflamed skin
(Figure 6g). However, BMV treatment further augments this
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Figure 3. NF-jB Decoy delivery in normal porcine skin. (a) Colocalization of
0.5% NF-kB Decoy (green) and nuclei (red) appears as yellow-orange in
overlay images (left panel). Non-treated skin used as a negative control for
avidin staining shows minimum background flourescence (right panel).
Sections were observed at an original magnification of  40, bar¼ 25 mm.
(b) PCR pharmacokinetics of the pig skin detects nanogram levels of Decoy.
Increased uptake of Decoy is evident in tape-stripped samples. Data are
plotted as mean7SEM (n¼6, Po0.02 for normal pig skin and Po0.002 for
tape-stripped pig skin). These results are representative of two independent
experiments.
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Figure 4. NF-jB Decoy inhibits proinflammatory regulators, decreases proliferation and induces apoptosis. (a) Immunohistochemistry demonstrating 1%
NF-kB Decoy and BMV suppress cytokine production. Inflamed ears after 14 days of treatment (b.i.d.) were stained with anti-IL-1b, anti-TNF-a, anti-macrophage
inflammatory protein 2-a precursor, and anti-ICAM antibody. Sections were observed at an original magnification of  40, bar¼25 mm. (b) Ubiquitin-
normalized mRNA levels of key proinflammatory genes from inflamed ears treated with 1% scramble ODN, 1% topical NF-kB Decoy, or BMV for 7 days b.i.d.
Data are plotted as mean7SEM (n¼ 4). These results are representative of three independent experiments. (c) Dust-mite-induced inflamed ears were analyzed
for apoptosis by TUNEL assay (upper panel) and for proliferation using Ki67staining (lower panel) after 2 days of treatment with BMV or 1% NF-kB Decoy.
Sections were observed at an original magnification of  20, bar¼100 mm. (d) Quantitative representation of mitotic and apoptotic indices as percent-positive
cells in epidermis and dermis (Figure 4c). Cells were quantitated from six independent fields from three independent samples. Statistically significant differences
in apoptotic index observed for NF-kB Decoy and BMV as compared to inflamed controls (Po0.0001). For mitotic index: compare to inflamed sample Po0.006
for NF-kB Decoy and Po0.0003 for BMV. Data are plotted as mean7SEM. These results are representative of three independent experiments.
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expression (Figure 6g). The inflammation-associated CK17
mRNA levels were not induced in this inflammation model
(data not shown). Collectively, these data indicated that
topical NF-kB Decoy treatment restored inflammation-
induced compromised barrier function and did not induce
inflammation-associated CK genes.
DISCUSSION
NF-kB is an important therapeutic target in AD, since it plays
a crucial role in the coordinated transactivation of key
cytokines and adhesion molecules involved in the pathogen-
esis of this disease (Leung, 2000; Kraft et al., 2002; Nakamura
et al., 2002a; Zheng et al., 2003; Furukawa et al., 2004). NF-
kB Decoy is a potential therapeutic agent based on target-
specific drug design and modulation of NF-kB-specific genes
with reduced local and systemic side effects. Successful
topical treatment using ODNs are limited due to challenges
presented by the skin barrier, however, the compromised SC
associated with AD presents more favorable conditions for
topical ODN delivery. We demonstrate a novel mechanism
of inhibiting Th1- and Th2-mediated skin inflammation using
topical NF-kB Decoy leading to the normalization of local
immune function and tissue homeostasis. In addition, NF-kB
Decoy treatment is comparable to BMV treatment without
steroid-associated side effects.
Here we show efficient drug delivery to inflamed mouse
skin by immunohistological analysis as revealed by the
presence of NF-kB Decoy in cells pivotal for disease
progression and maintenance, including keratinocytes, resi-
dent antigen-presenting cells–Langerhans cells, mast cells,
CD4þ T cells, and macrophages (Boguniewicz and Leung,
2001; Qin et al., 2001). Importantly, this study is first to
demonstrate effective topical decoy delivery into porcine skin
tissue. Preliminary results show equivalent delivery in human
skin from a single donor using a Bronaugh flow-through
diffusion cell and 0.5% (H3)-NF-kB Decoy (data not shown).
Interestingly, we observe a similar efficacy profile of
NF-kB Decoy and BMV treatment. This may be explained by
the fact that glucocorticoids interact directly with NF-kB via
glucocorticoid receptors, thereby inhibiting the expression
of similar genes (Barnes, 1998; Asadullah et al., 2002).
Accordingly, both NF-kB Decoy and BMV inhibit Th1 and
Th2 cytokines, such as chemokine (C–C motif) receptor 3,
IL-4, IL-13, IFNg, IL-1b, and TNF-a; factors of pathological
relevance in cutaneous inflammation (Leung and Geha,
1981; Leung, 1997b). Our data also suggests that topical
NF-kB Decoy and BMV treatment enhances apoptosis
in inflamed tissue. This is consistent with the studies
showing NF-kB protects the normal epithelium from apop-
tosis, whereas, NF-kB blockade enhances susceptibility to
programmed cell death (Karin, 1998; Seitz et al., 2000).
Apoptosis of activated lymphocytes by NF-kB Decoy is most
likely caused through the inhibition of NF-kB-responsive
pro-survival genes (Martinon et al., 2000; Qin et al., 2001).
This is of great importance, since other studies have shown
that induction of apoptosis is crucial for the treatment of
chronic inflammatory diseases and most likely exhibits a
common final pathway of superior treatment therapies (Fuss
et al., 1999; Goedkoop et al., 2004; Catrina et al., 2005).
Hence, topical NF-kB Decoy, similar to BMV, exerts its
anti-inflammatory action by blocking expression of major
inflammatory regulators and by inducing apoptosis of
inflamed skin cells.
Skin atrophy is a frequent complication associated with
prolonged steroid use (Sheu et al., 1998; Schacke et al., 2002;
Kao et al., 2003). Our results demonstrate that NF-kB
Decoy therapy provides anti-inflammatory activity without
atrophogenic effects. Extensive molecular investigations of
steroid-induced skin atrophy have shown reduced expression
of several major components of the extracellular matrix:
collagen I and III, tenascin C, elastin, and the family of matrix
metallo-proteases (Booth et al., 1982; Oikarinen et al., 1998;
Kimata et al., 2001; Nuutinen et al., 2003). Expression of
these extracellular matrix genes following 14 days of topical
NF-kB Decoy application remained unperturbed, while a
30–50% reduction was observed following BMV treatment.
These results support previous studies where BMV, in contrast
to topical calcineurin inhibitors, affects collagen synthesis
(Autio et al., 1996; Kikuchi and Tagami, 2002).
Further support of these findings is provided by a GLP
dermal porcine toxicology study, in which three doses (1 mg/
kg, 3.3 kg/mg, and 20 mg/kg/day) of topical NF-kB Decoy
treatment (b.i.d.) for 28 days on both male and female
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Figure 5. NF-jB Decoy does not cause skin atrophy. (a) Normal mouse ears
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plotted as mean7SEM (n¼ 8, *Po0.0001). These results are representative of
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6677 mm. Sections were observed at an original magnification of  40,
bar¼ 25 mm. (c) Ubiquitin-normalized mRNA levels of extracellular matrix
genes, collagen I (Col I), collagen III (Col III), Tenascin C, and elastin after
treatment with 1% NF-kB Decoy or BMV. Data are plotted as mean7SEM
(n¼4, BMV samples were compared to normal samples Po0.001 for Col I
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representative of three independent experiments.
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minipigs did not cause pig skin hyperproliferation or atrophy
(Table S1). Additionally, the same study suggests a lack of
systemic side effects, since the weights of tissues including
heart, kidney, liver, spleen, lung, and thymus was not
adversely influenced (Table S2). This finding was supported
by a pharmocokinetic study using PCR pharmacokinetic
analysis showing no systemic ODN accumulation (lower
limit of quantification; 1.3 ng ODN /ml plasma). These
observations indicate that topical NF-kB Decoy treatment
may not pose a risk for local or systemic side effects.
Although flares associated with extended steroid treatment
are common, the precise molecular mechanisms of this
phenomenon are not well understood. Topical steroid
treatment in humans leads to increased TEWL, barrier
disruption, and loss of lamellar bodies in the SC (Sheu
et al., 1991; Sheu et al., 1997). Studies on hairless mice have
also shown increases in TEWL and loss of SC integrity with
short-term steroid treatment (Sheu et al., 1998; Kao et al.,
2001; Kao et al., 2003). Our finding illustrates that a key
advantage of NF-kB Decoy treatment is its ability to restore
TEWL to normal levels, while BMV treatment fails to reduce
AD-associated TEWL in inflamed mouse skin.
Cutaneous response to injury results in the release of cyto-
kines, growth factors, and the expression of inflammation-
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associated CKs (Le et al., 1996; Kuijpers et al., 1997; Komine
et al., 2000). Others show, that the induction of CK6, CK16,
and CK17 is associated with inflammation (Jiang et al., 1993;
Leigh et al., 1995; Takahashi et al., 1998). Importantly, skin-
derived antileucoproteinase, CK6 and CK16 are induced in
several hyperplastic skin disorders including psoriasis and AD
(Nonomura et al., 1994; Leigh et al., 1995; Jensen
et al., 2004). In conjunction with these findings, we demon-
strate that hyperproliferation-associated CK6 and CK16 and
inflammation associated skin-derived antileucoproteinase
expression were dramatically augmented by BMV treatment
as compared to non-treated inflamed lesions, while reduced
by topical NF-kB Decoy application. Of note, mRNA levels
of other SC regulators related to epidermal permeability, such
as transglutaminase 1 and 3, loricrin, fillagrin, involucrin, and
K1/K10 were not affected in Dp-Ag-induced inflammation
with either drug treatment (data not shown). Collectively, this
suggests that BMV treatment leads to SC barrier dysfunction
allowing increased exogenous allergenic challenges resulting
in disease flare-ups.
While these initial results regarding the safety of NF-kB
Decoy are very encouraging, further research is necessary to
determine the long-term tolerability of such a drug. For
instance, in light of recent black box warnings for topical
calcineurin inhibitors, long-term effects of topical NF-kB
Decoy application on carcinogenicity need to be carefully
addressed. Preliminary experiments in the DMBAþ12-O-
tetradecanoylphorbol 13-acetate skin cancer mouse model
indicate the drug does not enhance tumor formation when
given topically for 21 weeks (data not shown). However,
more studies are needed to fully understand the drug’s
long-term effect not only on carcinogenicity but also on
tissue responsiveness to bacterial and viral challenges. To
that extent, we are presently performing functional antigen
challenge as well as comprehensive gene profiling studies
that will reveal additional information on the safety and
efficacy of NF-kB Decoy therapy. Currently, topical NF-kB
Decoy is being investigated in Phase 1/2 clinical trials in mild
to moderate AD patients.
This study clearly demonstrates that topical NF-kB Decoy
has exciting potential for the treatment of AD and other
cutaneous inflammatory disorders with an added advantage
of restoring skin homeostasis necessary to avoid recurrence
of disease.
MATERIALS AND METHODS
The medical ethical committee of Corgentech Incorporation
approved all described studies. Our animal studies were performed
in accordance with IACUC guidelines.
Oligonucleotide synthesis
The NF-kB Decoy is a 19 base pair (molecular weight of 13 kDa)
double-stranded deoxyribonucleic acid comprised of a random
mixture of R- and S-chiral forms of ODN. The sequence of the NF-kB
Decoy used in this study was: CGTK 153 –50-AGTTGAGGACTTTCC
AGGC-30 and CGTK 154 – 50-GCCTGGAAAGTCCTCAACT-30. The
scrambled ODN sequence was CGTK 103 – 50-CAGTAGTATGTG
AGCCTGC-30 and CGTK 104 -50-GCAGGCTCACATACTACTG-30.
All ODN used were phosphorothioates and were annealed by
combining equal molarities of each strand at room temperature.
Indicated concentrations of ODN were added to Corgentech’s
gel-based formulation, for topical application.
Animal models
Dust-mite Ag (Dp)-induced dermatitis was induced in 6-week-old
male NC/Nga mice (Charles River Lab, Wilmington, MA). Animals
were injected intradermally with 5 mg of Dp extract (Greer
Laboratories, Lenoir, NC) dissolved in saline on the ventral side of
their right ears on days 0, 2, 4, 7, 9, and 11. Starting on day 12, the
Dp-injected ear was topically treated two times a day for 11–14 days
with 20ml of vehicle, vehicle containing indicated doses of NF-kB
Decoy, non-specific scramble ODN, or topical 0.1% BMV as the
positive control. The ear thickness was measured with snap caliper
(Oditest, Dyer Inc., Lancaster, PA) 24 hours after each intradermal
injection or treatment. TEWL measurements: TEWL in Dp-induced
inflamed ears was measured using a Tewameter water analyzer
(Courage and Khazaka, Cologne, Germany). Inflamed ears were
treated with scramble ODN, 1% NF-kB Decoy, or BMV for 14 days
(b.i.d.). Ears were analyzed 16–18 hours after the last application of
either scramble ODN, 1% NF-kB Decoy, or BMV.
Electrophoretic mobility shift assay
The NF-kB gel shift assays were performed as follows: a double-
stranded ODN containing a consensus NF-kB-binding site from the
IL-6 promoter (50-TGTGGGATTTTCCCATGACTC-30) was end-la-
beled with g32P-ATP using T4 Polynucleotide Kinase (Promega,
Madison, WI). In all, 5mg of a nuclear extract prepared from Dp-
Ag-injected ears was incubated with 35 fmol of radiolabeled probe
in the presence or absence of indicated antibodies. The identity of
NF-kB proteins contained in complexes bound to the radiolabeled
ODN probe were identified by pre-incubating the reactions for
10 minutes with antibodies specific for each member of the NF-kB
family prior to the addition of the radiolabeled probe (all antibodies
were purchased from Active Motif (Carlsbad, CA) (p65 and p50) or
Santa Cruz Biotechnology, Santa Cruz, CA (p52, RelB, cRel).
NF-YA/SP1/p65 TransAM assay
To assess the relative affinities of NF-kB Decoy for a NF-YA/SP1/p65
containing complex, TransAM assays (Active Motif, Carlsbad, CA)
were utilized. The assay was performed according to the manu-
facturer’s instructions. Briefly, a double-stranded ODN containing
the consensus NF-YA/SP1/p65-binding sequence was immobilized
on a 96-well plate. A nuclear extract prepared from NC/Nga-
inflamed ears or activated THP-1 cells were incubated and allowed
to bind to the immobilized ODN. The unbound material was
washed away and the bound NF-YA/SP1/p65 detected using an
antibody that specifically recognizes NF-YA/SP1. The NF-YA/SP1/
p65 antibody was detected by a secondary antibody labeled with
horseradish peroxidase, and the amount of horseradish peroxidase in
each well was measured using a colorimetric substrate reaction and
read using a micro-plate spectrophotometer.
Histology
Hematoxylin and eosin staining. Dp-injected mice ears were
formalin-fixed, paraffin-embedded and 5-mM sections were then
stained with hematoxylin and eosin. Mast cells staining: deparaffinized
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and rehydrated sections were stained in toluidine blue working
solution (1% toluidine blue stock solution). Eosinophils staining:
formalin-fixed, paraffin-embedded tissue samples were stained with
congo red for detection of eosionophils. Apoptosis and mitotic
index: formalin-fixed, paraffin-embedded tissue samples were used
to identify apoptotic cells by the TUNEL assay. All the reagents were
provided in the ‘‘In Situ Cell Death Detection Kit’’ (Roche,
Indianapolis, IN, Cat. no. 1 684 795). Formalin-fixed, paraffin-
embedded tissue samples were also used to identify proliferating
cells using Ki67 rabbit mAb (NeoMarkers Cat. no. RM-9106, Lab
Vision Corp., Fremont, CA).
NF-kB Decoy localization. Cryosections were used for coloca-
lization of 1% biotinylated NF-kB Decoy with various cells in
inflamed skin. After fixation in 2% paraformaldehyde, sections
were blocked with Goat Ig (Sigma, St Louis, MO). Primary antibodies
include rat anti-mouse CD4 (R&D Systems, Minneapolis, MN), rat
anti-mouse CD117 (BD, San Diego, CA), rabbit anti-mouse CD207-
Langerin (Imgenex, San Diego, CA), rat anti-mouse MCP-1 (Abcam,
Cambridge, UK), rat IgG2b Iso (BD), and rabbit Ig
Iso (Sigma 10 mg/ml). Secondary antibodies include Alexa 546
SAV (Molecular Probes, Eugene, OR), goat anti-rat Alexa 546,
goat anti-rabbit Alexa 546 (Molecular Probes). Images were taken at
 60 original magnification, using laser scanning confocal
microscppy. For pig skin, 0.5% biotinylated NF-kB Decoy was
applied at 30 ml/cm2 area on the back of a light skinned
female Yorkshire pig for 24 hours. Skin was washed thoroughly
with phosphate-buffered saline to remove any remaining formula-
tion. Duct tape from Intertape Polymer Group (Sarasota, FL)
was used and the skin was tape stripped 20 times. The biotinylated
NF-kB Decoy was visualized using AlexaFluor488-streptavidin
(Molecular Probes) and counterstained with Hoechst stain for
nuclear colocalization.
Immunoflourescence. Cryosections were used for IL-1b, TNF-k,
macrophage inflammatory protein 2-a precursor and ICAM localiza-
tion. Primary antibodies include PE-rat anti-mouse IL-1b (R&D
Systems), PE-rat anti-mouse TNF (BD), rat anti-mouse macrophage
inflammatory protein 2-a precursor (R&D Systems), rat anti-mouse
ICAM (Serotec), rat IgG2b isotype control (BD) (Sigma). Secondary
antibodies include goat anti-rat Alexa 546 (Molecular Probes,
Eugene, OR).
Collagen staining. Formalin-fixed, paraffin-embedded tissue sam-
ples were used to stain collagen using sirius red F3B dye. In the
dermis this stain specifically detects collagen type III. Sections are
stained with Alcian blue pH¼ 2.5, to delineate cartilage prior to
picro-sirius red staining (0.1%).
RNA analysis
Total RNA was isolated from the ears using Qiazol (Qiagen,
Valencia, CA). The first-strand cDNA was synthesized using Reverse
Transcriptase II (Invitrogen, Carlsbad, CA). The expression of the
mouse genes was assayed by real-time quantitative PCR with an ABI
PRISM 7900 Sequence Detector System (Applied Biosystems, Foster
City, CA). Primers were designed to cross at least one intron based
on the most current genome sequences using software Primer3
(Whitehead Institute for Biomedical Research, MIT). The quantitative
PCR was performed using TaqMan PCR reagent kits according to the
manufacturer’s protocol (Applied Biosystems). Extracellular matrix
genes and cytokine mRNA levels were normalized to ubiquitin
mRNA levels and expressed relative to normal untreated samples.
PCR pharmacokinetics analysis
The amount of NF-kB Decoy in skin tissue was determined by using
in-house developed (patent pending) method. Simply, the method is
based on real-time quantitative PCR-based assay with specific
primer design and reagent modifications. The skin samples undergo
alkaline lysis (using P2 buffer of Qiagen Miniprep Kit). Quantitative
measure of Decoy in samples is obtained by comparing with the
standard curve that is prepared by spiking known amounts of
Decoy to the same biological matrix (or sample without Decoy
treatment). The final value of Decoy in tissue was normalized to the
net tissue weight.
Statistical analysis
Plotted data were expressed as mean7SEM. Under the assumption
of Gaussian distribution of all our measurements, difference between
two groups were compared by Student’s t-test (paired or unpaired as
appropriate) with one tails and equal variance setting. P-values
o0.05 were considered significant.
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